<DOC>
	<DOCNO>NCT01209000</DOCNO>
	<brief_summary>Minimal change disease ( MCD ) , focal segmental glomerulosclerosis ( FSGS ) , Membranous nephropathy ( MN ) , generate enormous individual societal financial burden , account approximately 12 % prevalent end stage renal disease ( ESRD ) case ( 2005 ) annual cost US $ 3 billion . However , clinical classification diseases widely believe inadequate scientific community . Given poor understanding MCD/FSGS MN biology , surprise available therapy imperfect . The therapy lack clear biological basis , many family experience , often beneficial , fact may significantly toxic . Given observation , essential research conduct address serious obstacle effectively care patient . In response request application National Institutes Health , Office Rare Diseases ( NIH , ORD ) creation Rare Disease Clinical Research Consortia , number affiliated university join together The NephCure Foundation NIDDK , ORDR , University Michigan collaboration towards establishment Nephrotic Syndrome ( NS ) Rare Diseases Clinical Research Consortium . Through consortium investigator hope understand fundamental biology rare disease aim bank long-term observational data correspond biological specimen researcher access enrich .</brief_summary>
	<brief_title>Nephrotic Syndrome Study Network</brief_title>
	<detailed_description>Idiopathic Nephrotic Syndrome ( NS ) rare disease syndrome responsible approximately 12 % cause end-stage kidney disease ( ESRD ) 20 % ESRD child . Treatment strategy Focal Segmental Glomerulosclerosis ( FSGS ) , Minimal Change Disease ( MCD ) Membranous Nephropathy ( MN ) , major cause NS , include high dose prolonged steroid therapy , cyclophosphamide , cyclosporine A , tacrolimus , mycophenolate mofetil immunosuppressive agent , carry significant side effect . Failure obtain remission use current treatment approach frequently result progression ESRD associate cost , morbidity , mortality . In North American Pediatric Renal Trials Collaborative Studies ( NAPRTCS ) registry , half pediatric patient Steroid Resistant Nephrotic Syndrome require renal replacement therapy within two year enrol disease registry . FSGS also high recurrence rate follow kidney transplantation ( 30-40 % ) common recurrent disease lead allograft loss . The prevailing classification Nephrotic Syndrome categorize patient FSGS , MCD , MN , absence underlying cause , glomerular histology show specific histological pattern . This classification adequately predict heterogeneous natural history patient FSGS , MCD , MN . Major advance understand pathogenesis FSGS MCD come last ten year identification several mutate gene responsible cause Steroid Resistant Nephrotic Syndrome ( SRNS ) present FSGS MCD histopathology human model organism . These functionally distinct genetic disorder present indistinguishable FSGS lesion histology confirm presence heterogeneous pathogenic mechanism current histological diagnosis . The limited understanding FSGS , MCD , MN biology human necessitate descriptive classification system heterogeneous disorder group together . This invariably consign heterogeneous patient therapeutic approach , use blunt immunosuppressive drug lack clear biological basis , often beneficial , complicate significant toxicity . The foregoing shortcoming make strong case concert innovative investigational strategy combine basic science , translational , clinical method employ study FSGS , MCD , MN . It reason Nephrotic Syndrome Study Network establish conduct clinical translational research patient FSGS/MCD MN .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<criteria>Cohort A ( biopsy cohort ) Patients present incipient clinical diagnosis FSGS/MCD MN pediatric participant previously biopsied , clinical diagnosis FSGS/MCD MN meeting follow inclusion criterion : Documented urinary protein excretion â‰¥1500 mg/24 hour spot protein : creatinine ratio equivalent time diagnosis within 3 month screening/eligibility visit . Scheduled renal biopsy Cohort B ( nonbiopsy , cNEPTUNE ) Age &lt; 19 year age Initial presentation &lt; 30 day immunosuppression therapy Proteinuria/nephrotic UA &gt; 2+ edema OR UA &gt; 2+ serum albumin &lt; 3 OR UPC &gt; 2g/g serum albumin &lt; 3 Exclusion Criteria ( Cohort A &amp; B ) : Prior solid organ transplant A clinical diagnosis glomerulopathy without diagnostic renal biopsy Clinical , serological histological evidence systemic lupus erythematosus ( SLE ) define ARA criterion . Patients membranous combination SLE exclude entity well define within International Society Nephrology/Renal Pathology Society category lupus nephritis , frequently overlap classification category SLE nephritis ( 68 ) Clinical histological evidence renal disease ( Alport , Nail Patella , Diabetic Nephropathy , IgAnephritis , monoclonal gammopathy ( multiple myeloma ) , genitourinary malformation vesicourethral reflux renal dysplasia ) Known systemic disease diagnosis time enrollment life expectancy le 6 month Unwillingness inability give comprehensive inform consent Unwillingness comply study procedure visit schedule Institutionalized individual ( e.g. , prisoner )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Focal Segmental Glomerulosclerosis</keyword>
	<keyword>Focal &amp; Segmental Glomerulosclerosis</keyword>
	<keyword>Focal Segmental Glomerulosclerosis</keyword>
	<keyword>FSGS</keyword>
	<keyword>Minimal change disease</keyword>
	<keyword>MCD</keyword>
	<keyword>Membranous Nephropathy</keyword>
	<keyword>MN</keyword>
	<keyword>Nephrotic Syndrome</keyword>
	<keyword>Neph Syndrome</keyword>
	<keyword>NEPTUNE</keyword>
	<keyword>NephCure</keyword>
	<keyword>Halpin</keyword>
</DOC>